Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development

Shirin Kashfi, M.Sc.1,2, Maryam Peymani, Ph.D.2, Kamran Ghaedi, Ph.D.2,3, Hossein Baharvand, Ph.D.1,4, Mohammad Hossein Nasr Esfahani, Ph.D.2,* Mohammad Javan, Ph.D.4,5*

1. Department of Developmental Biology, University of Science and Culture, Tehran, Iran
2. Department of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
3. Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
4. Department of Stem Cell and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
5. Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

*Corresponding Addresses: P.O. BOX: 81593-58686, Department of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
P.O.Box: 14115-331, Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Emails: mjavan@modares.ac.ir, mh_nasr@royaninstitute.org

Received: 28/Feb/2016, Accepted: 28/Aug/2016

Abstract

Objective: Due to recent progress in production of human embryonic stem cell-derived oligodendrocyte progenitor cells (hESC-OPCs) for ameliorating myelin disease such as multiple sclerosis (MS) and the role of purinergic signaling in OPCs development, we evaluated the profile of purinergic receptors expression during development of OPCs from hESC.

Materials and Methods: In this experimental study, we used reverse transcription and quantitative polymerase chain reaction (RT-qPCR) to obtain more information about potential roles of purinergic receptors during in vitro production of hESC-OPCs. We first determined the expression level of different subtypes of purinergic receptors in hESCs, embryoid bodies (EBs), and hESC-OPCs. The effects of A1 adenosine receptor (A1AR) activation on hESC-OPCs development were subsequently examined.

Results: hESCs and OPCs had different mRNA expression levels of the AR subtypes. ARs mRNA were expressed in the EB stage, except for A2AAR. We observed expressions of several P2X (P2X1, 2, 3, 4, 5, 7) and P2Y (P2Y1, 2, 4, 6, 11-14) genes in hESCs. hESC-OPCs expressed different subtypes of P2X (P2X1, 2, 3, 4, 5, 7) and P2Y (P2Y1, 2, 4, 6, 11-14). Except for P2X and P2Y, all other P2X and P2Y purinergic receptor subtypes expressed in EBs. We also indicate that A1AR might be involved in modulating gene expression levels of cell cycle regulators in an agonist and/or dose-dependent manner.

Conclusion: Elucidation of the expression pattern of purinergic receptors and the effects of different subtypes of these receptors in hESC-OPCs may have a promising role in future cell-based therapy or drug design for demyelinating disease.

Keywords: Human Embryonic Stem Cell, Oligodendrocyte Progenitor Cell, Purinergic Receptors, A, Adenosine Receptor

Citation: Kashfi Sh, Peymani M, Ghaedi K, Baharvand H, Nasr Esfahani MH, Javan M. Purinergic receptor expression and potential association with human embryonic stem cell-derived oligodendrocyte progenitor cell development. Cell J. 2017; 19(3): 386-402. doi: 10.22074/cellj.2017.3906.
Introduction

Oligodendrocytes are responsible for synthesis and maintenance of myelin sheaths around the axons as well as providing trophic support for axons in the central nervous system (CNS) (1, 2). Consequently, an aberration in the function of oligodendrocytes which occurs under different pathological conditions causes detrimental neurological disorders (3-5). The oligodendrocyte progenitor cells (OPCs) in adult brains are believed to serve as potential sources for the generation of mature oligodendrocytes which replace lost oligodendrocytes and remyelinate bared axons (6). However, due to local obstacles against endogenous OPCs proliferation, migration or differentiation, adult remyelination is insufficient in demyelinating neurological disorders such as multiple sclerosis (MS) (7, 8). Therefore, efforts have been directed to replace lost cells and enhance endogenous remyelination by transplanting OPCs from different sources (9, 10) or by potentiating endogenous OPCs for remyelination and functional recovery (11).

Several studies have stated that axonal release of purines (ATP or adenosine) occurs during neuronal activity (12, 13), which may promote myelination in the CNS (12, 14). It has been also reported that stimulation of purinergic signaling enhanced remyelination by transplanting OPCs from different sources (9, 10) or by potentiating endogenous OPCs for remyelination and functional recovery (11).

The increasing need for pluripotent stem cell derived-OPC replacement therapy and multiple roles of purines and purinergic receptors in the CNS have prompted us to perform a comprehensive study of the pattern changes of purinergic receptor mRNA expression during differentiation of hESC to OPCs. In this regard, we can characterize mRNA expression profiles of these receptors in the human embryonic stem cell (hESC) line RH6 and cell aggregates, known as embryoid bodies (EBs) which resemble an early stage of normal development (20). This data can provide a valuable resource for future studies on the effects of the purinergic system during hESC differentiation to oligodendrocyte lineage cells. According to researchers, a focus on characterization of the physiological state of ESC derived cells can improve the success of cell-based therapies (21). We have attempted to demonstrate the effects of A₁AR activation in hESC-derived OPC (hESC-OPCs) developmental processes such as proliferation and differentiation in vitro. To the best of our knowledge, this is the first report that presents a profile of purinergic receptor expression in hESCs and derivatives during OPC production and the role of A₁AR signaling in hESC-OPCs.

Materials and Methods

Chemicals were purchased from Gibco (USA) or Sigma-Aldrich (USA) unless indicated otherwise. Materials purchased from Sigma-Aldrich included platelet derived growth factor-AA (PDGF-AA), epidermal growth factor (EGF), triiodothyronine (T3), Matrigel, all-trans retinoic acid (RA), paraformaldehyde, Triton, 4’,6-diamidino-2-phenylindole (DAPI), 5-bromo-2’-deoxyuridine (BrdU), and N6-cyclopentyladenosine (CPA). Materials purchased from Gibco included DMEM/F12, insulin-transferrin-selenium (ITS), N2 supplement, fetal bovine serum (FBS), penicillin/streptomycin, L-glutamine, non-essential amino acids (NEAA), and B27 supplement. We purchased 5’-Chloro-5’-deoxy-endo-2-norbornyl adenosine (5’Cl5’-d(±)-ENBA) from Tocris and 8-Cyclopentyl-1-3-dipropyl xanthine (DPCPX) from Abcam.
Derivation of oligodendrocyte progenitor cells from human embryonic stem cells

For this experimental study, the RH6 hESC line was obtained from Royan Institute (Iran). hESCs were maintained and expanded under feeder-free culture conditions in the presence of 300 ng/ml of human basic fibroblast growth factor (bFGF, Royan Institute, Iran) using a previously described protocol (22). hESCs were differentiated according to a published protocol (23) with some modifications. Briefly, dissociated colonies were placed in low attachment dishes in 50% feeder-free media (FFM) and 50% glial restriction media (GRM) that contained 20 ng/ml EGF for 2 days. On day 1 the media contained 300 ng/ml bFGF. On day 2 it was supplemented with bFGF and 10 μM RA. This media was subsequently replaced with 100% GRM and supplemented with RA for an additional 8 days. Cells were then exposed for 18 days to GRM without RA. At day 28, yellow spheres were plated in 12-well plates coated with Matrigel for a period of 7 days. Cultures were then passaged using Accutase (Millipore, USA) and we excluded any remnant spheres. Cells were replated on Matrigel and cultured in GRM. The total time for the differentiation protocol was 35 days. Figure 1A represents a summary of the protocol used in this study.

Cell collection and total RNA isolation

Cell collection was performed at three stages of the oligodendrocyte differentiation procedure: hESC (day 0), 10 day-old EBs, and the hESC-OPC stage. All samples were collected and the total RNA extracted according to the RNeasy Mini Kit (Qiagen, Germany) procedure. RNA concentration was measured on a Biochrom WPA (Biowave, UK) spectrophotometer. The 260/280 ratio was not less than 1.8 for RNA samples included in this study.

Reverse transcription and quantitative polymerase chain reaction

DNA was degraded with the use of a DNaseI, RNase-free kit (Takara, Japan) and cDNA was subsequently prepared with the Takara cDNA Synthesis Kit based on the manufacturer’s instructions to a final concentration of 25 ng/μl.

We determined the expression levels of all purinergic receptors, oligodendrocyte lineage transcription factor 2 (OLIG2), platelet-derived growth factor-α (PDGFRα), proteolipid protein 1 (PLP1), galactosylceramidase (GALC), cell cycle regulator including cyclin-dependent kinase inhibitor 1A (CDKN1A) that encodes for the p21Cip1 protein, cyclin-dependent kinase inhibitor 1B (CDKN1B) which encodes for the p27Kip1 protein, cyclin D1 (CCND1), and a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR mixture contained 10 µl SYBR Green PCR Master Mix (Takara, Japan), 3 pmole of each primer, and 25 ng of cDNA for each reaction in a final volume of 20 µl. Specific primer pairs (Table 1) were designed by the Beacon Designer (version 7.2) and Oligo 7 primer analysis software (version 7). Detection and quantification of each sample was performed by the Applied Biosystems StepOnePlus Real-Time PCR system (ABI, USA). In order to further verify the specificity of the RT-qPCR assays, we performed each experiment with samples that lacked the cDNA template along with samples that contained positive control cDNA obtained from appropriate human tissues proven to have high expression levels of the desired genes (17, 24).

Expression levels of genes were estimated by the delta-delta Ct method. All Ct values calculated from the target genes were normalized to GAPDH in each sample and calibrated using calculations from each selected gene of the control sample. For expression levels of purinergic genes all normalized values were calibrated by using calculations from each selected gene of the P1 or P2 subfamily in hESCs. Each experiment consisted of at least three independent replicates for each stage and each replicate included three identical samples. The normalized calibrated value was given by the equation $2^{-\Delta\Delta Ct}$. Amplification products were resolved on 2% agarose gel (Invitrogen, USA), stained with ethidium bromide (Sinaclone, Iran), and the fragment sizes were determined by comparisons to known DNA standards.
Purinergic Receptors in hESC-OPCs

A

B

C

D

E
Fig. 1: Different stages of human embryonic stem cell (hESC) differentiation into oligodendrocyte progenitor cells (OPCs) and characterization of hES-OPCs. A, Schematic presentation of the steps for hESC differentiation into OPCs as described in the materials and methods section. B, Undifferentiated hESC colonies. C, hESC-derived embryoid bodies (EB). D, Plated EB. E, hESC-OPCs (scale bars: 200 µm, insert in E: 50 µm). F, mRNA expression levels of platelet-derived growth factor-α (PDGFRα) and oligodendrocyte lineage transcription factor 2 (OLIG2) in cultured hES-OPCs. Data is expressed as mean ± SEM. G, hESC-OPCs recognized by the cell surface marker PDGFRα according to flow cytometry analysis. Immunostaining for H, PDGFRα, and I, NG2 surface markers expression in hESC-OPCs. Green; PDGFRα or NG2, blue; DAPI (scale bar: 50 µm). bFGF; Basic fibroblast growth factor, FFM; Feeder-free media, GRM; Glial restriction media, and RA; Retinoic acid.
## Table 1: Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) primers

| Gene | Primer sequence (5’-3’) | Accession number | Amplicon size (bp) |
|------|-------------------------|------------------|-------------------|
| A₁   | F: CTTCTTTGTGTGGGTGCTR: CTGCTTGCGGATTAGGTAG | NM_000674.2 | 79 |
| A₂ₐ  | F: CCCAGAGGTGACATTTGACR: GCAGCCAGAGAGGTGAAAG | NM_000675.4 | 87 |
| A₂₈  | F: TCAGTAGTAAAGCTCCAAGR: ACCATAAACAAGCGACAG | NM_000676.2 | 133 |
| A₃   | F: AAAGCCTGGTGATCGGCTGT | NM_000677.3 | 134 |
| A₁ | F: ATCTGTGCTCTTCCGAGCTR: ACGTGATGTGCTGATTTAG | NM-00558.2 | 98 |
| P₂X₁ | F: TGGGACTGTGACCTGGACCTR: TGGTACTGAGGAAATAGAG | NM_001226.3 | 106 |
| P₂X₂ | F: CATCTCCTGCTCAACTCCTR: TTCAGCCTAGTCTCATTCA | NM-002559.3 | 78 |
| P₂X₃ | F: CTTCTCCAAACACTCCCCACTARC: GTCTTGCGGTTCTCACCATT | NM_001256796.1 | 107 |
| P₂X₄ | F: GTAAATCTCCTGCCTAGTTT | NM_001204519.1 | 197 |
| P₂X₅ | F: CTTCTCTGTTGCTGTGATR: GGGATAGGGAGGTGGATTA | NM_001159554.1 | 82 |
| P₂X₆ | F: GCCCAACTACACCCACAGAGA | NM_002562.5 | 161 |
| P₂X₇ | F: GAATCTCCAAACACCTCTCTGR: GCGTTACCTCCGACCTG | NM_002563.3 | 175 |
| P₂X₈ | F: GTGGAGCTGGACTGTTGGTTR: ATAGGGTTGGGGCACTAAAG | NM_002564.2 | 98 |
| P₂X₉ | F: AAACCATGCGGAGAATTAGAGR: AGAAGGGCAAGGTTGTAAG | NM_002565.3 | 150 |
| P₂Y₁ | F: GACTGGAGACGCAAGAACAACR: GCAGGACAGCAACAGACA | NM_002566.4 | 100 |
| P₂Y₂ | F: CAATCTACCTCCCCACTCGR: GCGTTATGTCTGAAAG | NM_002567.2 | 100 |
| P₂Y₅ | F: GCCGACTTGGATAGTACGACTAT | NM_001081455.1 | 165 |
| P₂Y₆ | F: GTGGAGGTGGCTGCACTGAGG | NM_001201402.1 | 113 |
| P₂Y₇ | F: AGCGACCTTCCCCTCACTCCTC | NM_002046.3 | 107 |
| PDGFRA | F: TAACTGTTGGATCTGCTCAAACAC | NM_006206.4 | 135 |
| OLG2 | F: GAAGAGAGGCGCTTGTTAGGR: GCGTTATGTCTGAAAG | NM_000586.3 | 175 |
| PLP1 | F: AGCAATGGAGCGGTAGTGAGR: CAAGGAAAGGGCGTGAGAAG | NM_176894.2 | 109 |
| GALC | F: TCGTTTCCTCAGCTCATCTCR: CTCCCTCCTCCTGACACAAG | NM_001201402.1 | 113 |
| CDKN1A | F: AGCGACCTTCCCCTCCTC | NM_000389.4 | 99 |
| CDKN1B | F: GCGAAGGAGGTTCAGCTCTC | NM_004064.4 | 109 |
| CCND1 | F: GCCTACCTGCCTAGCTCTCTCTATT | NM_053056 | 179 |
| GAPDH | F: CCACTCCTCCACCTTTTGCGR: CCACTGACCCCACTGTGAG | NM_002046.3 | 107 |
Proliferation and apoptosis assays

We used the BrdU incorporation assay to evaluate the fraction of hESC-OPC that underwent proliferation in vitro. hESC-OPCs were first cultured in 12-well plates (3×10^4 cells/cm^2) and synchronized. Then, cells were exposed to GRM medium that contained A,AR selective agonists (0.5 µM CPA or 1 µM 5’Cl5’d-(-)-ENBA) for 48 hours. For the BrdU assay, hESC-OPCs were labeled with BrdU at concentration of 10 µM overnight before the study was terminated. Cells were fixed and immunocytofluorescence staining performed according to manufacturer protocols and counterstained with DAPI (3 ng/ml) for 5 minutes. Proliferation rate was calculated as the ratio of BrdU/DAPI+ nuclei per microscopic fields. A total of 1000 cells per coverslips were sampled to obtain a mean for each well.

Plasma membrane binding of annexin V (IQ product) was used to detect and quantify apoptotic hESC-OPCs after they were treated with A,AR selective agonists for 48 hours with respect to untreated cells according to the manufacturer’s protocol. Detached cells were collected by centrifugation and resuspended in annexin V binding buffer. Then, cells were incubated on ice with 10 µl of annexin V-FITC for 20 minutes. In order to discriminate between apoptotic and dead cells, propidium iodide (PI) was used for 10 minutes at room temperature. Cells were analyzed and quantitated by flow cytometry.

Differentiation assay

For differentiation studies, we incubated the cells with GRM that contained growth factors and 0.5 µM CPA or 1 µM 5’Cl5’d-(-)-ENBA for 48 hours. RT-qPCR expression levels of the cell cycle regulator genes CDKN1A and CDKN1B which encode p21^{Cip1} and p27^{Kip1}, two cell cycle dependent kinase inhibitors (CDKIs), and CCND1 which encodes cyclin D1 (a regulator of G1 cyclin dependent kinases) have been compared with untreated cells. mRNA expression levels of PLP1 and GALC, two markers of oligodendrocyte lineage cells, were evaluated to determine the differentiation stages of treated and untreated cells.

Immunocytofluorescence

For immunocytofluorescence, cells were washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 10 minutes. Permeabilization was carried out either with 0.1% Triton X-100 for 15 minutes for PDGFRalpha and BrdU or 0.05% Triton X-100 for 30 minutes for NG2. Cells were washed twice and incubated overnight at 4°C with primary antibody. The primary antibodies included rabbit anti-PDGFRalpha (1:200, Cell Signaling, USA), rabbit anti-NG2 (1:200, Millipore, USA), and mouse anti-BrdU (1:750, Sigma, USA). Cells were washed three times, then incubated with secondary antibodies in 5 mg/ml bovine serum albumin (BSA) at 37°C for 1 hour and rinsed three times. The secondary antibody was goat anti-rabbit FITC (1:80, Sigma, USA) and Alexa fluor 568 goat anti-mouse IgG (1:300, Invitrogen, USA). The negative controls consisted of matched isotype controls. The nuclei were stained with DAPI. The stained cells were analyzed with a fluorescent microscope (Olympus, Japan) and images acquired with an Olympus DP70 camera (Olympus, Japan).

Flow cytometry

Analysis of hESC-OPCs was performed by a FACS Calibur flow cytometer (Becton Dickinson, USA) with a 488 nm argon laser. Briefly, the cells were dissociated with accutase (Millipore, USA) at 37°C for 5 minutes. Then, cells were washed twice with PBS by centrifugation at 1500 rpm for 10 minutes. The cells were fixed with 4% paraformaldehyde in PBS for 10 minutes. After washing twice with PBS, the cells were permeabilized with 0.1% triton X-100 for 15 minutes. Then, cells were washed twice and triturated with a narrow glass Pasteur pipette to prepare a single cell suspension. The primary antibody, rabbit anti-PDGFRalpha (1:200, Cell Signaling, USA), was added to the cells and the suspension was allowed to incubate at 37°C for 2 hours. A secondary antibody, goat anti-rabbit IgG-FITC (1:50, Chemicon, USA), was added to the cells, after which they were incubated at 37°C for 45 minutes. The negative control was the sample without primary antibodies. Analysis of annexin V/PI staining by flow cytometry was performed as previously described. A forward and side scatter gate was used to select target cells from the aggregates. We calculated a total of 10000 events for each sample with data analysis by WinMDI 2.9 software. Green fluorescence was detected by the FL1-H detector and displayed in the histogram.

Statistical analysis

Statistical analysis was performed using either ANOVA followed by a multiple comparison post
**Results**

**Differentiation and characterization of human embryonic stem cells to oligodendrocyte progenitor cells**

Previous work has shown that hESCs can be efficiently differentiated into OPCs through defined stages (23). We began differentiation of OPCs by culturing hESCs in a suspension to induce EB formation. For further differentiation, we chose EBs that had adequate morphologies and seeded them (Fig.1A). After 25 days, most cells exhibited a typical OPC morphology characterized by small bipolar cells (25). The morphology of cells in different stages is illustrated in Figure 1B-E. RT-qPCR analysis indicated that hESC-OPCs expressed high levels of PDGFRα and OLIG2 genes (Fig.1F).

In order to further confirm the success of OPC differentiation, we examined the expression of PDGFRα, a surface marker for OPCs, at the protein level by flow cytometry (Fig.1G) and immunostaining (Fig.1H). Flow cytometry analysis indicated that approximately 90% of our cells were PDGFRα positive. These cells also expressed nerve-glial antigen 2 (NG2) sulfated proteoglican, another OPC surface marker, as confirmed by immunostaining (Fig.1I).

**P1 receptor subfamily mRNA expression in human embryonic stem cells, embryoid bodies, and human embryonic stem cell-derived oligodendrocyte progenitor cells**

We used RT-qPCR to determine the level of mRNA expression in four different subtypes of P1 receptors. Gene expression analysis revealed that all subtypes of the P1 receptor family A1AR, A2AR, A2BR, and A3AR were present in hESCs, albeit with different degrees of expression (Fig.2A). The level of A1AR and A2BR mRNA decreased significantly in the EB stage compared to hESCs (P<0.05) but A3AR showed the highest level of expression in EBs. Cells in this stage were negative for A2AR. In hESC-OPCs, the mRNA of target genes A1AR, A2AR, A2BR, and A3AR could be detected, although the expression level of A2BR decreased and A2AR mRNA expression increased significantly in hESC-OPCs compared to hESCs or EBs (P<0.05, Fig.2B).

---

**Fig.2:** Different levels of the P1 receptor subfamily mRNA expressions in human embryonic stem cells (hESCs), embryoid bodies (EBs), and hESC-derived oligodendrocyte progenitor cells (hESC-OPCs). A. Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) products obtained from hESCs and separated on gel agarose. B. The profile of P1 receptor mRNA expression in EBs and hESC-OPCs as examined by RT-qPCR. RT-qPCR was performed as described in the materials and methods section. Bars represent the mean of triplicate independent experiments ± SEM. a, b, and c indicate significant differences between hESCs and EBs, hESCs and hESC-OPCs, hESC-OPCs and EB samples, respectively at P<0.05.
P2X receptor subfamily mRNA expression in human embryonic stem cells, embryoid bodies, and human embryonic stem cell-derived oligodendrocyte progenitor cells

Figure 3A shows the mRNA expression levels of the P2X subfamily receptors in hESCs. P2X7 did not express in EBs, but significantly up-regulated in hESC-OPCs compared to undifferentiated hESCs (P<0.05). We observed a significant increase in the expression level of P2X2, P2X4, and P2X9 in EBs compared to hESCs, whereas P2X5 had a significant downregulation in this stage (P<0.05). Comparative analysis of mRNA expression levels of these receptors in hESC-OPCs showed downregulation of them compared to their expression levels in hESCs. Expression of the P2X7 receptor in hESC-OPCs showed a non-significant increase compared to hESCs (P>0.05). The current data showed that we had no P2X2 expression in any of the cell populations. Interestingly, P2X7 had the highest expression in hESC-OPCs, but its expression did not show significant changes during OPC differentiation (P>0.05). Our data confirmed the expression of all subtypes of P2X receptors except for P2X6 in hESC-OPCs (Fig.3B).

P2Y receptor subfamily mRNA expression in human embryonic stem cells, embryoid bodies, and human embryonic stem cell-derived oligodendrocyte progenitor cells

Figure 4A shows the results of P2Y receptor mRNA expression analyses in hESCs. hESCs expressed P2Y2, P2Y4, P2Y6, P2Y7, P2Y11, P2Y12, and P2Y13. OPCs differentiated from hESCs expressed all types of P2Y receptor subtypes at the transcriptional level without any significant change compared to hESCs (P>0.05). In the EB stage, all P2Y receptors showed a trend for increased expression, with the most significant increase observed for P2Y6 and P2Y4 receptors compared with hESCs (P<0.05). There were no significant changes observed between the expression levels of P2Y10, P2Y12, P2Y13, and P2Y14 receptors (P>0.05, Fig.4B). Of note, the expression levels of all P2Y receptor subtypes down-regulated when cells differentiated to OPCs.

Effects of A1 adenosine receptor activation on human embryonic stem cell-derived oligodendrocyte progenitor cell proliferation

We examined the effect of A1AR activation on hESC-OPCs by selective A1AR agonists, CPA (0.5 µM) and 5’Cl5’d-(±)-ENBA (1 µM), for 48 hours on proliferation rate of hESC-OPCs in the presence of growth factors by using BrdU incorporation assays. As shown in Figure 5A, the percentage of BrdU+ cells did not significantly change between control and CPA treated cells (P>0.05), while the number of BrdU+ cells decreased significantly after 5’Cl5’d-(±)-ENBA treatment (P<0.05). Nonetheless, the annexin V assay showed no significant difference in cell survival between the different groups (P>0.05, Fig.5B).

Effects of A1 adenosine receptor activation on human embryonic stem cell-derived oligodendrocyte progenitor cell differentiation

Although, it is not sufficient, it is necessary for OPCs to exit from cell cycle when they start to differentiate (26). We examined the mRNA expression level of certain cell cycle regulators after 48 hours of treatment with CPA (0.5 µM) and 5’Cl5’d-(±)-ENBA (1 µM) compared with untreated hESC-OPCs. We chose cyclin D1, p21(Cip1), and p27Kip1 because they have a critical role in regulation of OPC differentiation (27-29). Figure 6A and B represents the results of p21(Cip1), p27Kip1, and CCND1 gene expressions. We have observed increased levels of p21(Cip1) and p27Kip1 expressions after treatment with both A1AR selective agonists. However, 5’Cl5’d-(±)-ENBA significantly upregulated the expression of both cell cycle-dependent kinase inhibitors (P<0.05). The expression level of CCND1 upregulated significantly after treatment with CPA (P<0.05), however we did not observe this finding for 5’Cl5’d-(±)-ENBA (P>0.05).

In order to determine to which extent changes in expression levels of the cell cycle regulators link to differentiation of hESC-OPCs, we analyzed the gene expression levels of PLP1 and GALC (Fig.6C, D). PLP1 expression level did not changed significantly after treatment with both A1AR agonists (P>0.05), although we observed slight downregulation of PLP1 after 5’Cl5’d-(±)-ENBA (1 µM) treatment. Interestingly, CPA (0.5 µM) significantly decreased the level of GALC mRNA expression while significant increase in GALC expression was seen after 5’Cl5’d-(±)-ENBA (1 µM) treatment (P<0.05). The selectivity of A1AR agonist action in each experiment was determined as DPCPX (0.5 or 1 µM) antagonized the effects of CPA (0.5 µM) or 5’Cl5’d-(±)-ENBA (1 µM) respectively.
Fig. 3: Different levels of P2X receptor subfamily mRNA expression in human embryonic stem cells (hESCs), embryoid bodies (EBs), and hESC-derived oligodendrocyte progenitor cells (hESC-OPCs). A. Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) products obtained from hESCs and separated on gel agarose. B. The profile of P2X receptor mRNA expression in EBs and hESC-OPCs as examined by RT-qPCR. RT-qPCR was performed as described in the materials and methods section. Bars represent the mean of triplicate independent experiments ± SEM. a, b, and c indicate significant differences between hESCs and EBs, hESCs and hESC-OPCs, and hESC-OPCs and EB samples respectively at P<0.05.
Fig. 4: Different level of P2Y receptor subfamily mRNA expression in human embryonic stem cells (hESCs), embryoid bodies (EBs), and hESC-derived oligodendrocyte progenitor cells hESC-OPCs. A. Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) products obtained from hESCs and separated on gel agarose. B. The profile of P2Y receptor mRNA expression in EBs and hESC-OPCs as examined by RT-qPCR. RT-qPCR was performed as described in the materials and methods section. Bars represent the mean of triplicate independent experiments ± SEM. a, b, and c indicate significant differences between hESCs and EBs, hESCs and hESC-OPCs, and hESC-OPCs and EB samples respectively at P < 0.05.
Fig. 5: The percentage of proliferative and surviving of human embryonic stem cell-derived oligodendrocyte progenitor cells (hESC-OPCs) after treatment with CPA (0.5 µM) or 5’Cl5’d-(±)-ENBA (1 µM) for 48 hours in each experiment. Data are obtained from BrdU incorporation and the annexin V affinity assay as described in the materials and methods section. A. The percentage of BrdU+ cells from the control (n=3, 40 random fields, 1000 cells per coverslip) and B. The percentage of total surviving cells. Bars represent the mean of the experiments performed in triplicate ± SEM. *; Significant differences between untreated and treated groups at P<0.05.

Fig. 6: The mRNA expression level of three cell cycle regulators (p21\(^{Cip1}\), p27\(^{Kip1}\), CCND1), and two genes that represent oligodendrocyte lineage cell markers [proteolipid protein 1 (PLP1) and galactosylceramidase (GALC)] in human embryonic stem cell-derived oligodendrocyte progenitor cells (hESC-OPCs). Data obtained after 48 hours of treatment with CPA (0.5 µM) or 5’Cl5’d-(±)-ENBA (1 µM) and was compared with the control as measured by RT-qPCR (described in the materials and methods section). A, B. Relative fold expression level of p21\(^{Cip1}\), p27\(^{Kip1}\), CCND1, C and D. Relative fold expression level of PLP1 and GALC. Bars represent the mean of independent experiments performed in triplicate ± SEM. *; Significant differences between untreated and treated groups at P<0.05.
Discussion

Oligodendrocyte dysfunction and myelin damage lead to diseases such as MS, one of the most debilitating neurological disorders (30). Experimental models of demyelinating disorders show that myelin regeneration is mainly mediated by OPCs (31, 32). Observations in MS patients have shown that OPCs present in the lesion area could not effectively differentiate and contribute to the remyelination process (33). Purinergic signaling which is believed to play a potential role in early development of organs (34, 35), including the CNS (36), may be a possible solution for enhancing differentiation capacity of endogenous or exogenous OPC.

In the current study, among the four subtypes of AR, A<sub>1</sub>AR mRNA had the highest expression in hESCs followed by A<sub>2A</sub>AR, A<sub>2B</sub>AR, and A<sub>3</sub>AR. Our data also revealed that the expressions of A<sub>1</sub>AR and A<sub>2B</sub>AR significantly down-regulated in the EB stage compared to undifferentiated hESCs. A<sub>3</sub>AR mRNA had no expression in the EB stage, whereas we observed up-regulated expression of A<sub>1</sub>AR. The increase or decrease in the expression level of these receptors possibly indicated that they might be involved in the early stages of differentiation.

Assessment of the expression pattern of P1 receptors in hESC-OPCs showed that the expressions of A<sub>1</sub>AR, A<sub>2A</sub>AR, A<sub>2B</sub>AR, and A<sub>3</sub>AR moderately up-regulated in these cells compared to hESCs or the EB stage; however, this difference was statistically significant only for A<sub>1</sub>AR. Unlike A<sub>1</sub>AR, the A<sub>2B</sub>AR expression down-regulated in hESC-OPCs compared to hESCs. Consistently, the expression of all subtypes of P1 receptor subtypes was previously reported in rodent OPCs (12). The observed enhanced expression of A<sub>1</sub>AR in hESC-OPCs was consistent with bioinformatics data on the expression of the A<sub>1</sub>AR transcript in mice at the neurulation stage (http://www.ncbi.nlm.nih.gov/uniGene).

Our results revealed that hESCs expressed P<sub>2X</sub>, P<sub>2X</sub>, P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub> receptors but not the P<sub>2X</sub> receptor. In addition, these cells expressed all P2Y subtype receptors at the transcriptional level. Previously, RT-PCR has been used to verify the expressions of P<sub>2X</sub>, P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub> receptors in mice ESCs and pharmacological assays demonstrated that ATP acted on P2 receptors which increased proliferation of mouse ESCs (37). It has been demonstrated that in human hiPSC and hESC lines, aberrational expression of the housekeeping gene hypoxanthine guanine phosphoribosyl transferase (an enzyme involved in purine biosynthesis) led to down-regulation of P<sub>2Y</sub> expression which caused abnormal development of the dopaminergic pathway (38). These observations showed the complexity and importance of studying purinergic receptor expressions during early developmental stages.

The comparative expression profile of P<sub>2X</sub> receptors in EB stage and ESCs revealed that P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub> but not P<sub>2X</sub>, transcriptionally up-regulated. RT-qPCR analysis showed that although all P2Y receptor subtypes were transcriptionally active in the EB stage, P<sub>2Y</sub> had the highest level of expression. Changes in gene expression levels of certain types of purinergic receptors have been previously shown in vitro in the course of neural differentiation (39) or during early development, in vivo (35, 40). Of note, we studied expression of P2 receptor subtypes in the EB stage after RA treatment. Expression levels of P2 receptors have been frequently reported to be regulated by RA, a well-known morphogen agent (41, 42).

In the present study, P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub> up-regulated in hESC-OPCs whereas other genes, P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub>, down-regulated. Our RT-qPCR analysis showed the expression of all subtypes of P2Y purinergic receptors in these cells. However, their degrees of expression were mainly reduced relative to hESCs or the EB stage. Among this subtype, P<sub>2Y</sub> showed the highest expression level in hESC-OPCs. Previously, cultured rat OPCs also expressed different P<sub>2X</sub> (P<sub>2X</sub>, P<sub>2X</sub>, P<sub>2X</sub>, P<sub>2X</sub>, and P<sub>2X</sub>) receptors (18). By functional analysis, the presence of P<sub>2X</sub>, and several P2Y (P<sub>2Y</sub>, P<sub>2Y</sub>, P<sub>2Y</sub>, P<sub>2Y</sub>, P<sub>2Y</sub>, P<sub>2Y</sub>) receptors were reported in OPCs (36). The results of the current study showed some similarities with previous studies.

Oligodendrocyte development is a complicated process that involves the interplay of numerous factors. It has been shown that AR and/or some P2Y receptors may be involved in oligodendrocyte progenitor differentiation in rodents (12, 18). Although the effects of purinergic receptors activation on human oligodendrocyte lineage cells development have not been investigated yet, we focused on the effects of A<sub>1</sub>AR activation on hESC-
OPC development by considering the following criteria: i. A1,AR mRNA expression was seen in the first part of the current study, ii. It was demonstrated that A1,AR activation played a prominent role in mediating neuroprotection and neuromodulatory effects of adenosine in CNS [reviewed in (43)], iii. A1,AR activation ameliorated the severity of EAE and increased remyelination in an animal model of MS (15, 44), and iv. A1,AR agonists often affect cardiovascular function such as decreased heart rate or blood pressure (45). However, it was reported that a novel series of A1,AR agonists did not have such unintended adverse effects (46), including 5’C15’D-(±)-ENBA (47).

Our data demonstrated that CPA did not significantly affect hESc-OPCs proliferation (P>0.05), which supported a previous study on rodent OPCs (48). However, the proliferation rate of these cells decreased significantly after treatment with 5’C15’D-(±)-ENBA. Of note, changes in agonist structure have been shown to alter the ability of A1,AR to activate different signaling pathways with diverse potency and efficacy due to different receptor conformations. So the current study results probably present another example of "functional selectivity", which has been described as "agonist-dependent receptor signaling" (49), and needs additional in depth study. However, these results may also reflect the dose-dependent effects of selective agonists.

We proposed that these results might be due to events associated with modulation of cell cycle regulators. Hence, we have focused on expression pattern of those canonical cell cycle components which play a role in G1 progression or oligodendrocyte cell cycle exit and differentiation. This hypothesis is supported by several studies on cell cycle regulation of the oligodendrocyte lineage cells (50-53). Our results have indicated that CPA treatment up-regulated gene expression levels of p21Cip1 and p27Kip1 non-significantly while significantly up-regulation of CYCLIN D1. We observed a distinct pattern in expression profile of these cell cycle regulators after 5’C15’D-(±)-ENBA treatment with significantly increased p21Cip1 and p27Kip1 levels accompanied by non-significant downregulation of CYCLIN D1 expression. Cyclin D1 kinase activities decreased in G1-arrested and differentiated oligodendrocytes (52).

The Kip/Cip family of cyclin dependent kinase inhibitors (including p21Cip1 and p27Kip1) has been involved in the regulation of oligodendrocyte development. Overexpression of p27Kip1 increased the efficiency of oligodendrocyte differentiation from induced pluripotent stem cells (29) and an increased level of proliferated OPCs has been seen in p27Kip1 null mutant mice (50). p21Cip1 is not required for cell cycle exit, but plays a role in OPC differentiation (51). However, the complex relationship between p27Kip1, cyclin D1, and other cell cycle proteins such as cdk4 must be considered. Some studies have suggested that Kip/Cip CDKIs are activators of cyclin D-CDK complex assembly. Then, the cyclin D-CDK complex can sequester the Kip/Cip family of CDKIs from cyclin E-cdk2 complexes and allow cell cycle progression (54, 55). Other studies have suggested that high expression of CDKIs can repress CDK activity (53, 56). Considering these data, it is not surprising that we have found no significant difference between CPA treated and untreated cells in our study despite elevated CYCLIN D1 gene expression. Also, there is the same mRNA expression profile for p21Cip1, p27Kip1, and CYCLIN D1 in oligodendrocytes which has been extracted from schizophrenia patients’ brains. Patients suffer from schizophrenia face to condition that mature oligodendrocytes re-enter to cell cycle and failure to differentiate (28). In addition, a significant decrease in proliferation rate of hESc-OPC after 5’C15’D-(±)-ENBA treatment was in accord with significant upregulation of p21Cip1 and p27Kip1. This observation supported previous studies which reported that highly expressed p27Kip1 could suppress CDKs (56). Upregulation of p21Cip1 and, especially p27Kip1, have appeared to be part of intrinsic mechanisms which cause cell cycle arrest and possibly initiation of differentiation.

Next, we sought to determine the extent to which cell cycle gene expression changes in this system accompanied with progress in oligodendrocyte differentiation by determining the mRNA expression level of some special markers of oligodendrocyte developmental stages. PLP expression has been shown to occur very early in OPCs in the spinal cord where it plays a role in normal OPCs migration. PLP expression downregulated as cells progressed through their subsequent developmental stages and then upregulated as OPCs matured into myelinating
changes in protein expressions regarding the expression and distribution of these expanded and complemented previous studies. hESCs, EBs, and hESC-OPCs has answered regarding the extent to which these mRNA expression levels correlate with protein expression.

Acknowledgments

This research was financially supported by a grant from Royan Institute for Biotechnology (ACECR), Isfahan, Iran. There is no conflict of interest.

References

1. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001; 81(2): 871-927.
2. Du Y, Dreyfus CF. Oligodendrocytes as providers of growth factors. J Neurosci Res. 2002; 68(6): 647-654.
3. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 1996; 6(3): 243-257.
4. Back SA, Han BH, Luo NL, Chritchon CA, Xanhouddakis S, Tam J, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia–ischemia. J Neurosci. 2002; 22(2): 455-63.
5. Almad A, Sahinkaya FR, McGtigue DM. Oligodendrocyte fate after spinal cord injury. Neurotherapeutics. 2011; 8(2): 262-273.
6. Zawadzka M, Rivers LE, Fancy SP, Zhao C, Tripathi R, Jemen F, et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. 2010; 6(6): 578-590.
7. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci. 2002; 3(9): 705-714.
8. Billiards SS, Haynes RL, Folketh RD, Borenstein NS, Trachtenberg FL, Rowitch DH, et al. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol. 2008; 18(2): 153-163.
9. Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci. 2005;
Purinergic Receptors in hESC-OPCs

25(19): 4694-4705.

10. Wang S, Bates J, Li X, Schanz S, Chandler-Millitello D, Levine C, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell. 2013; 12(2): 252-264.

11. Dubois-Dalcq M, French-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron. 2005; 48(1): 9-12.

12. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron. 2002; 36(5): 855-868.

13. Fields RD, Ni Y. Nonsynaptic communication through ATP release from volume-activated anion channels in axons. Sci Signal. 2010; 3(142): ra73.

14. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron. 2006; 49(6): 823-832.

15. Aghari AA, Azarnia M, Mirnajafi-Zadeh J, Javan M. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies. J Neuroil. 2013; 325(1): 22-28.

16. Fredholm BB, Uzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4): 527-552.

17. Burnatay G. Physiological and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007; 87(2): 659-797.

18. Agresti C, Meomartini M, Amadio S, Ambrosi E, Serafini B, Franchini L, et al. Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and development. Glia. 2005; 50(2): 132-144.

19. Coppi E, Cellai L, Maruà G, Pugliese AM, Pedata F. Adenosine A2A receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures. Neuropharmacology. 2013; 73: 301-310.

20. Itskovitz-Eldor J, Schuldiner M, Karsenti D, Eden A, Yanuka O, Amit M, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med. 2000; 6(2): 88-95.

21. Forestay O, Romanyuk N, Verkhratsky A, Sykova E, Dayanithi G. Plasticity of calcium signaling cascades in human embryonic stem cell-derived neural precursors. Stem Cells Dev. 2013; 22(10): 1506-1521.

22. Pakzad M, Tontchi M, Taei A, Seifinejad A, Hassani SN, Baharvand H. Presence of a ROCK inhibitor in extracellular matrix supports more undifferentiated growth of feeder-free human embryonic and induced pluripotent stem cells upon passing. Stem Cell Rev. 2010; 6(1): 96-107.

23. Poyua A, Satarian L, Kiani S, Javan M, Baharvand H. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. PLoS One. 2011; 6(11): e27925.

24. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004; 240: 31-304.

25. Buchet D, Baron-Van Evercooren A. In search of human oligodendroglia for myelin repair. Neurosci Lett. 2009; 456(3): 112-119.

26. Ghiani CA, Eisen AM, Yuan X, DePinho RA, McBain CJ, Gallo V. Neurotransmitter receptor activation triggers p27 (Kip1) and p21 (CIP1) accumulation and G1 cell cycle arrest in oligodendrocyte progenitors. Development. 1999; 126(5): 1077-1090.

27. Bosone I, Cavalla P, Chiaod-Piat L, Vito ND, Schiffer D. Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligodendrogliomas. Neuropathology. 2001; 21(3): 155-161.

28. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB, et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology. 2008; 33(12): 2993-3009.

29. Tamaki S, Tomukoto Y. Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells. In Vitro Cell Dev Biol Anim. 2014; 50(8): 778-785.

30. Duncan ID, Grever WE, Zhang SC. Repair of myelin disease: strategies and progress in animal models. Mol Med Today. 1997; 3(12): 554-561.

31. Keirstead HS, Blakemore WF. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Adv Exp Med Biol. 1999; 468: 183-197.

32. Picard-Riera N, Decker L, Delarasse C, Goude K, Nait-Oumesmar B, Liblau R, et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci USA. 2002; 99(20): 13211-13216.

33. Fancy SP, Chan JR, Baraninz SE, Franklin RJ, Rowitch DH. Myelin regeneration: a recapitulation of development? Annu Rev Neurosci. 2011; 34: 21-43.

34. Burnstock G, Verkhratsky A. Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis. 2010; 1(1): e9.

35. Massé K, Dale N. Purines as potential morphogens during embryonic development. Purinergic Signal. 2012; 8(3): 303-321.

36. Fields RD, Burnstock G. Purinergic signalling in neuronglia interactions. Nat Rev Neurosci. 2006; 7(6): 423-436.

37. Heo JS, Han HJ. ATP stimulates mouse embryonic stem cell proliferation via protein kinase C, phosphatidylinositol 3-kinase/Akt, and mitogen-activated protein kinase signaling pathways. Stem Cells. 2006; 24(12): 2637-2648.

38. Mastrangelo L, Kim JE, Miyahora A, Kang TH, Friedmann T. Purinergic signaling in human pluripotent stem cells is regulated by the housekeeping gene encoding hypoxanthine guanine phosphoribosyltransferase. Proc Natl Acad Sci USA. 2012; 109(9): 3377-3382.

39. Resende RR, Majumder P, Gomes KN, Britto LR, Ulrich H. P19 embryonal carcinoma cells as in vitro model for studying purinergic receptor expression and modulation of N-methyl-D-aspartate–glutamate and acetylcholine receptors during neuronal differentiation. Neuroscience. 2007; 146(3): 1169-1181.

40. Massé K, Bhamra S, Eason R, Dale N, Jones EA. Purine-mediated signalling triggers eye development. Nature. 2007; 449(7165): 1058-1062.

41. Tozaki-Saitoh H, Koizumi S, Sato Y, Tsuda M, Nagao T, Iinoue K. Retinoic acid increase p2x2 receptor expression through the 5’-flanking region of p2rx2 gene in rat phaeochromocytoma pc-12 cells. Mol Pharmacol. 2006; 70(1): 319-328.

42. Gorodeski GI. Expression, regulation, and function of P2X4 purinergic receptor in human cervical epithelial cells. Am J Physiol Cell Physiol. 2002; 282(1): C84-C93.

43. Sperlah G, Vizi ES. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Curr Top Med Chem. 2011; 11(8): 1034-1046.
44. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci. 2004; 24(6): 1521-1529.
45. Stella L, Bernino L, Maione S, De Novellis V, Rossi F. Cardiovascular effects of adenosine and its analogs in anaesthetized rats. Life Sci. 1993; 53(10): 755-763.
46. Korboukh I, Hull-Ryde EA, Rittiner JE, Randhawa AS, Coleman J, Fitzpatrick BJ, et al. Orally active adenosine A1 receptor agonists with antinociceptive effects in mice. J Med Chem. 2012; 55(14): 6467-6477.
47. Luongo L, Petrilli R, Gatta L, Giordano C, Guida F, Vita P, et al. 5'-Chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions. Molecules. 2012; 17(12): 13712-13726.
48. Othman T, Yan H, Rivkees SA. Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia. 2003; 44(2): 166-172.
49. Cordeaux Y, Uzerman AP, Hill SJ. Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol. 2004; 143(6): 705-714.
50. Casaccia-Bonnefil P, Hardy RJ, Teng KK, Levine JM, Koff A, Chao MV. Loss of p27Kip1 function results in increased proliferative capacity of oligodendrocyte progenitors but unaltered timing of differentiation. Development. 1999; 126(15): 4027-4037.
51. Zezula J, Casaccia-Bonnefil P, Ezhevsky SA, Osterhout DJ, Levine JM, Dowdy SF, et al. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2001; 2(1): 27-34.
52. Huang Z, Tang XM, Cambi F. Down-regulation of the retinoblastoma protein (rb) is associated with rat oligodendrocyte differentiation. Mol Cell Neurosci. 2002; 19(2): 250-262.
53. Frederick TJ, Wood TL. IGF-I and FGF-2 coordinately enhance cyclin D1 and cyclin E–cdk2 association and activity to promote G1 progression in oligodendrocyte progenitor cells. Mol Cell Neurosci. 2004; 25(3): 480-492.
54. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(12): 1501-1512.
55. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003; 13(2): 65-70.
56. Bagui TK, Mohapatra S, Haura E, Pledger W. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol Cell Biol. 2003; 23(20): 7285-7290.
57. Harlow DE, Saul KE, Culp CM, Vesely EM, Macklin WB. Expression of proteolipid protein gene in spinal cord stem cells and early oligodendrocyte progenitor cells is dispensable for normal cell migration and myelination. J Neurosci. 2014; 34(4): 1333-1343.
58. Armati PJ, Mathey EK. The biology of oligodendrocytes. Cambridge: Cambridge University Press; 2010.
59. Casaccia-Bonnefil P, Tikoo R, Kyokawa H, Friedrich V, Chao MV, Koff A. Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. Genes Dev. 1997; 11(18): 2335-2346.
60. Durand B, Raff M. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays. 2000; 22(1): 64-71.